Infinator

Infinator is an early-stage biotechnology company focused on developing novel small molecule inhibitors for the treatment of cancer. The company's primary research centers on targeting Inosine-5'-monophosphate dehydrogenase (IMPDH), an enzyme essential for de novo guanine nucleotide biosynthesis which is often upregulated in rapidly proliferating cancer cells. By inhibiting this metabolic pathway, Infinator aims to disrupt the supply of nucleotides required for DNA and RNA synthesis in tumors. The company is currently advancing its lead programs through pre-clinical development to address various solid tumors and hematologic malignancies.